ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count - Milan 2023

Precision medicine considerations and inhalation efficacy in airway diseases

Chair(s): Ellen Tufvesson, Morten Hvidtfeldt

Session type: Poster session

ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count

Alvaro Martinez Mesa

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Unprimed electrostatic plastic bottle spacer delivered more salbutamol aerosol to airways than antistatic valved holding chambers

Hyouk-soo Kwon

Poster

Abstract

Can patients with FEV1 ?80% achieve improvements with benralizumab treatment? An ORBE II study subanalysis according to lung function

Marina Blanco Aparicio

Poster

Abstract

Late Breaking Abstract - Baseline characteristics impact on asthma exacerbation risk: individual patient trial data analysis

Pierluigi L. Paggiaro

Poster

Abstract

Absolute blood eosinophil counts among 3,763 healthy, asthmatic, and COPD subjects across India.

Priyanka Dhumal

Poster

Abstract

The impact of pretreatment blood eosinophils count (BEC) in the efficacy of Allergen Immunotherapy (AIT)

Antonios Christopoulos

Poster

Abstract

Improving access to biologic treatments for patients with severe asthma

Angela Cooper

Poster

Abstract

Fractional exhaled nitric oxide as a biomarker in patients with uncontrolled asthma

William Busse

Poster

Abstract

Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma.

Pp Hekking

Poster

Abstract

Long-term efficacy and tolerability of dupilumab in patients with moderate-to-severe type 2 asthma stratified by baseline characteristics

Michael E. Wechsler

Poster

Abstract

ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to smoking status

Carlos Martinez Rivera

Poster

Abstract

The effect of lung emptying on the breathing parameters characterizing the inhalation of aerosol drugs

Botond Havadtoi

Poster

Abstract

ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count

Alvaro Martinez Mesa

Poster

Abstract

The impact of smoking history on baseline characteristic in patients with severe asthma in the German Asthma Net (GAN)

Leonie Biener

Poster

Abstract

Consistency of Medication Delivery with Breath Actuated Technology when Simulated with Differing Inhalation/Exhalation Ratios

Mark Nagel

Poster

Abstract

The effect of lung emptying on the airway deposition of aerosol drugs

Janos Tamas Varga

Poster

Abstract

Aerosol delivery during high flow nasal oxygenation: breath enhanced nebulization.

Gerald Smaldone

Poster

Abstract

Treatable trait guided asthma management: biomarker changes and responder analysis

James Fingleton

Poster

Abstract

BDP/FF FDC protects against bronchospasm induced by PEG, a BNT162b2 COVID-19 vaccine excipient

Luigino Calzetta

Poster

Abstract

Late Breaking Abstract - Evaluation of the bronchoconstriction potential and safety profile of the novel environmentally-friendly HFA-152a propellant compared to the marketed HFA-134a propellant in a randomized clinical trial of adults with mild asthma

Michela Salvadori

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}